biOasis Technologies Inc. is an early-stage biopharmaceutical company. The Company is focused on research, development and commercialization of technologies and products intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. It is engaged in the development of vectors, such as Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). Its programs include Transcend Program, Oncology Program, Peptide Program, Transcendpep-siRNA Program and Collaborations and Internal Research and Development Program. The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin. It has initiated Transcend Vector Program for treatment of CNS symptoms of lysosomal storage diseases and studies to assess the therapeutic potential of the delivery of Herceptin to the brain for the treatment of brain metastases of HER2-positive breast cancer.